Cost-effectiveness of cancer drugs: Comparative analysis of the United States and England.

ABSTRACT:

Background

England's National Institute for Health and Care Excellence (NICE) and the US' Institute for Clinical and Economic Review (ICER) both conduct cost-effectiveness evaluations for new cancer drugs to help payers make drug coverage decisions. However, NICE and ICER assessments have been noted to reach different conclusions. We aim to better understand the degree to which their recommendations diverge and what drives these apparent differences.

Methods

We compared the methods and results of publicly available cost-effectiveness evaluations performed by ICER and NICE of similarly assessed cancer drugs. Assessments were compared based on incremental cost-effectiveness ratio, comparator treatment, price, recommendation, and the design of the economic evaluation.

Findin

SUBMITTER: Cherla A 

PROVIDER: S-EPMC7788430 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature